BEAM vs NEM · rev $63.5M vs P/E 14, rev $22.67B
Beam Therapeutics Inc (BEAM) versus Newmont Goldcorp Corp (NEM) — a side-by-side from cached financials, not a winner call.
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Latest reported BEAM revenue for 2024-12-31 was $63.5M. Net income was -$376.7M. Revenue was down 83.2% from 2023-12-31 to 2024-12-31. BEAM currently screens at market cap $2.01B.
Latest reported NEM revenue for 2025-12-31 was $22.67B. Net income was $7.08B. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
BEAM currently screens at market cap $2.01B. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Not investment advice. Open the BEAM and NEM stock pages for the full models.
Not investment advice.